Assignee
IMMUTEP SAS
FR·6 granted patents·10 pending applications·12 citations·filing 2014–2024
Top patents by PatentIndex Score
16 records- 0193US10940181B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Mar 9, 2021·3 cites·9 claims
- 0289US10874713B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2016·Granted Dec 29, 2020·4 cites·17 claims
- 0386US12214012B2Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2020·Granted Feb 4, 2025·1 cites·12 claims
- 0486US11684654B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Jun 27, 2023·1 cites·10 claims
- 0585US10736940B2Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2014·Granted Aug 11, 2020·3 cites·40 claims
- 0682US2023330182A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 0782US2025127856A1Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2024·Application pending·0 cites
- 0879US2023074746A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2022·Application pending·0 cites
- 0971US2023272107A1Anti-lag-3 antibodiesIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 1064US2025368714A1Treatment of cancerIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 1161US2024277804A1Triple combination therapyIMMUTEP SAS·Filed 2022·Application pending·0 cites
- 1255US2023210946A1Treatment of cancerIMMUTEP SAS·Filed 2021·Application pending·0 cites
- 1351US11680104B2Anti-LAG-3 antibodiesIMMUTEP SAS·Filed 2016·Granted Jun 20, 2023·0 cites·7 claims
- 1451US2022220199A1Anti-lag-3 binding moleculesIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 1550US2022341913A1AssaysIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 1640US2019361034A1Binding assayIMMUTEP SAS·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →